Outset Medical is set to speed up production and commercial use of its Tablo Hemodialysis System, which is designed for acute and chronic care markets.

The technology can reduce the cost and complexity of dialysis by integrating real-time water purification and dialysis fluid production in a single, compact system. The company refers to Tablo as a “dialysis clinic on wheels.” It requires only an electrical outlet and tap water to operate and is designed to look and feel like an intuitive consumer product. It features wireless data, sensor-based automation, and an animated touchscreen.

Mubadala Investment Company, a leading investor from Abu Dhabi, led a $132 million round of Series D equity financing that will allow the company to move its product on a commercial scale.

“Tablo offers patients and healthcare providers a new option for more flexible and convenient dialysis treatment, improving the dialysis experience while at the same time reducing overall dialysis spend,” said Leslie Trigg, Outset Medical’s Chief Executive Officer. “We are grateful to our investors for the opportunity to significantly impact the future of dialysis care.”